Safety and efficacy of sofosbuvir–velpatasvir–voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial-Reference-Cited by-同舟云学术

Safety and efficacy of sofosbuvir–velpatasvir–voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial

Published:2022-06 Issue:6 Volume:7 Page:542-551
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Gupta Neil,Manirambona Linda,Shumbusho Fabienne,Kabihizi Jules,Murangwa Anthere,Serumondo Janvier,Makuza Jean Damascene,Nsanzimana Sabin,Muvunyi Claude Mambo,Mukabatsinda Constance,Musabeyezu Emmanuel,Camus Gregory,Grant Philip M,Kateera Fredrick

Funder

Gilead Sciences

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference41 articles.

1. Global progress report on HIV, viral hepatitis and sexually transmitted infections 2021. Accountability for the global health sector strategies, 2016–2021: actions for impact,2021

2. Global progress on the elimination of viral hepatitis as a major public health threat: an analysis of WHO Member State responses 2017;Smith;JHEP Rep,2019

3. HCV market intelligence report 2021 and preliminary HBV market insights,2021

4. Achieving a high cure rate with direct-acting antivirals for chronic hepatitis C virus infection in Cameroon: a multi-clinic demonstration project;Coyer;Trop Med Int Health,2020

5. Treatment of hepatitis C genotypes 1 to 5 in sub-Saharan Africa using direct-acting antivirals;Sultan;Am J Trop Med Hyg,2020

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ‘Unusual’ HCV genotype subtypes: origin, distribution, sensitivity to direct-acting antiviral drugs and behaviour on antiviral treatment and retreatment;Gut;2024-05-23

2. Personalized care approaches to hepatitis C therapy: recent advances and future directions;Expert Review of Anti-infective Therapy;2024-03-11

3. Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus Retreatment in Difficult-to-treat Patients: A Real-life Observational Study from India;Journal of Clinical and Experimental Hepatology;2024-03

4. Hepatitis C Virus Infection in the Elderly in the Era of Direct-Acting Antivirals: Evidence from Clinical Trials and Real Life;Tropical Medicine and Infectious Disease;2023-11-18

5. Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis;Viruses;2023-06-30